Compare EXR & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EXR | INSM |
|---|---|---|
| Founded | 1977 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.3B | 30.1B |
| IPO Year | 2004 | 2000 |
| Metric | EXR | INSM |
|---|---|---|
| Price | $144.36 | $104.19 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 15 | 24 |
| Target Price | $144.80 | ★ $201.17 |
| AVG Volume (30 Days) | 1.1M | ★ 2.4M |
| Earning Date | 04-28-2026 | 05-07-2026 |
| Dividend Yield | ★ 4.61% | N/A |
| EPS Growth | ★ 13.90 | N/A |
| EPS | ★ 1.14 | N/A |
| Revenue | ★ $3,377,542,000.00 | N/A |
| Revenue This Year | N/A | $182.31 |
| Revenue Next Year | $3.63 | $65.19 |
| P/E Ratio | $125.92 | ★ N/A |
| Revenue Growth | ★ 3.70 | N/A |
| 52 Week Low | $125.71 | $64.85 |
| 52 Week High | $155.19 | $212.75 |
| Indicator | EXR | INSM |
|---|---|---|
| Relative Strength Index (RSI) | 57.95 | 25.01 |
| Support Level | $136.49 | N/A |
| Resistance Level | $148.85 | $166.81 |
| Average True Range (ATR) | 2.90 | 6.94 |
| MACD | 0.17 | -3.85 |
| Stochastic Oscillator | 85.11 | 12.12 |
Extra Space Storage is a fully integrated real estate investment trust that owns, operates, and manages more than 4,200 self-storage properties in 43 states, with over 330 million net rentable square feet of storage space. Of these properties, approximately one half is wholly owned, while some facilities are owned through joint ventures and others are owned by third parties and managed by Extra Space Storage in exchange for a management fee.
Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.